Blood Loss in Major Spine Surgery: Are There Effective Measures to Decrease Massive Hemorrhage in Major Spine Fusion Surgery?

Study Design. Systematic review. Objective. To determine the definition and incidence of significant hemorrhage in adult spine fusion surgery, and to assess whether measures to decrease hemorrhage are effective. Summary of Background Data. Significant hemorrhage and associated comorbidities in spine fusion surgery have not yet been clearly identified. Several preoperative and intraoperative techniques are currently available to reduce blood loss and transfusion requirements such as cell saver (CS), recombinant factor VIIa, and perioperative antifibrinolytic agents, such as aprotinin, tranexamic acid, and &egr;-aminocaproic acid. Their effectiveness and safety in spine surgery is uncertain. Methods. A systematic review of the English-language literature was undertaken for articles published between January 1990 and April 2009. Electronic databases and reference lists of key articles were searched to identify published studies examining blood loss in major spine surgery. Two independent reviewers assessed the quality of the literature using the Grading of Recommendations Assessment, Development, and Evaluation criteria. Disagreements were resolved by consensus. Results. A total of 90 articles were initially screened, and 17 ultimately met the predetermined inclusion criteria. No studies were found that attempted to define significant hemorrhage in adult spine surgery. We found that there is a high level of evidence that antifibrinolytic agents reduce blood loss and the need of transfusion in adult spine surgery; however, the safety profile of these agents is unclear. There is very low evidence to support the use of CS, recombinant factor VIIa, activated growth factor platelet gel, or normovolemic hemodilution as a method to prevent massive hemorrhage in spine fusion surgery. Conclusion. There is no consensus definition of significant hemorrhage in adult spine fusion surgery. However, definition in the anesthesiology literature of massive blood loss is somewhat arbitrary but is commonly accepted to entail loss of 1 volume of the patient's total blood (60 mL/kg in adults) in <24 hours. On the basis of the current literature, there is little support for routine use of CS during elective spinal surgery. Concerns related to the use of aprotinin were such that our panel of experts unanimously recommended against its use in spine surgery on the basis of the reports of increased complications. With respect to the antifibrinolytics of the lysine analog class (tranexamic acid and aminocaproic acid), on the basis of the available efficacy and safety data, we recommend that they be considered as possible agents to help reduce major hemorrhage in adult spine surgery.

[1]  Marc F Swiontkowski,et al.  Introducing levels of evidence to the journal , 2011, The Journal of bone and joint surgery. American volume.

[2]  K. Ker,et al.  Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. , 2011, The Cochrane database of systematic reviews.

[3]  J. Dettori,et al.  Methods for the Systematic Reviews on Patient Safety During Spine Surgery , 2010, Spine.

[4]  J. Gagne,et al.  Aprotinin and the risk of death and renal dysfunction in patients undergoing cardiac surgery: a meta‐analysis of epidemiologic studies , 2009, Pharmacoepidemiology and drug safety.

[5]  A. Laupacis,et al.  The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis , 2009, Canadian Medical Association Journal.

[6]  Y. R. Rampersaud,et al.  Tranexamic Acid Reduces Perioperative Blood Loss in Adult Patients Having Spinal Fusion Surgery , 2008, Anesthesia and analgesia.

[7]  N. A. Tayyab,et al.  Efficacy of Aprotinin as a Blood Conservation Technique for Adult Deformity Spinal Surgery: A Retrospective Study , 2008, Spine.

[8]  R. Martineau,et al.  A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. , 2008, The New England journal of medicine.

[9]  James D. Kang,et al.  Efficacy of Intraoperative Cell Saver in Decreasing Postoperative Blood Transfusions in Instrumented Posterior Lumbar Fusion Patients , 2008, Spine.

[10]  Peter Kruse,et al.  Recombinant Activated Factor VII in Spinal Surgery: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial , 2007, Spine.

[11]  J. Buchowski,et al.  Aprotinin May Decrease Blood Loss in Complex Adult Spinal Deformity Surgery, But It May Also Increase the Risk of Acute Renal Failure , 2007, Spine.

[12]  Jeremiah R. Brown,et al.  Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery , 2007, Circulation.

[13]  Peter Kruse,et al.  Cost and utilization of blood transfusion associated with spinal surgeries in the United States , 2007, European Spine Journal.

[14]  N. Epstein,et al.  Impact of Intraoperative Normovolemic Hemodilution on Transfusion Requirements for 68 Patients Undergoing Lumbar Laminectomies With Instrumented Posterolateral Fusion , 2006, Spine.

[15]  I. C. Tudor,et al.  The risk associated with aprotinin in cardiac surgery. , 2006, The New England journal of medicine.

[16]  A. Moxey,et al.  Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials , 2005, BMC cardiovascular disorders.

[17]  F. Castro Role of Activated Growth Factors in Lumbar Spinal Fusions , 2004, Journal of spinal disorders & techniques.

[18]  J. Cuenca,et al.  Predeposit autologous donation in spinal surgery: a multicentre study , 2004, European Spine Journal.

[19]  F. Brosstad,et al.  Tranexamic acid given into the wound reduces postoperative blood loss by half in major orthopaedic surgery. , 2003, The European journal of surgery. Supplement. : = Acta chirurgica. Supplement.

[20]  Andrea Furlan,et al.  Updated Method Guidelines for Systematic Reviews in the Cochrane Collaboration Back Review Group , 2003, Spine.

[21]  Safdar N. Khan,et al.  Factors Predicting Hospital Stay, Operative Time, Blood Loss, and Transfusion in Patients Undergoing Revision Posterior Lumbar Spine Decompression, Fusion, and Segmental Instrumentation , 2002, Spine.

[22]  A. Nanda,et al.  Autotransfusion by cell saver technique in surgery of lumbar and thoracic spinal fusion with instrumentation. , 2002, Journal of neurosurgery.

[23]  James D. Kang,et al.  Allogeneic Transfusion Requirements After Autologous Donations in Posterior Lumbar Surgeries , 2002, Spine.

[24]  O. Boachie-Adjei,et al.  The Efficacy of Antifibrinolytics in the Reduction of Blood Loss During Complex Adult Reconstructive Spine Surgery , 2001, Spine.

[25]  D. Benhamou,et al.  Reduction of blood loss and transfusion requirement by aprotinin in posterior lumbar spine fusion. , 1999, Anesthesia and analgesia.

[26]  H. Keim,et al.  Perioperative red blood cell salvage in spine surgery. A prospective analysis. , 1992, Clinical orthopaedics and related research.

[27]  H. Keim,et al.  Perioperative Red Blood Cell Salvage in Spine Surgery , 1992 .

[28]  Melissa S. Murphy,et al.  Fusions and Transfusions: An Analysis of Blood Loss and Autologous Replacement During Lumbar Fusions , 1989, Spine.

[29]  F. Horan The National Joint Registry for England and Wales. , 2003, The Journal of bone and joint surgery. British volume.